Table 3.
The relationship between dynamic change in albumin between pre-treatment and 12 weeks and overall survival in patients with NSCLC treated with first-line targeted therapy or immunotherapy-based therapy: univariate log-rank analysis.
| Albumin—Pre-Treatment | Albumin −12 weeks | n (%) | Overall Survival | |
|---|---|---|---|---|
| Median (IQR) | p | |||
| Targeted Therapy | ||||
| ≥35g/L | ≥35g/L | 59 (68) | 34.0 (18.5–70.8) | < 0.001 |
| ≥35g/L | <35g/L | 28 (32) | 10.4 (4.5–20.4) | |
| <35g/L | ≥35g/L | 18 (39) | 21.6 (18.7–n/r) | 0.021 |
| <35g/L | <35g/L | 28 (61) | 12.9 (6.7–20.4) | |
| Immunotherapy | ||||
| ≥35g/L | ≥35g/L | 91 (83) | n/r | 0.129 |
| ≥35g/L | <35g/L | 18 (17) | 19.7 (6.5–n/r) | |
| <35g/L | ≥35g/L | 25 (32) | 20.5 (11.7–n/r) | 0.011 |
| <35g/L | <35g/L | 53 (68) | 9.2 (5.1–20.5) | |
n/r = not reached. Bold italic values are statistically significant variables.